The use of tranexamic acid (TXA) has markedly increased since the results of the CRASH-II trial were published. In addition to its use in trauma, TXA has been evaluated and used in numerous other conditions, including post-partum hemorrhage and epistaxis. Recently, the HALT-IT Trial was published online in the Lancet, which evaluated the use of TXA in patients with acute gastrointestinal bleeding. In this podcast we discuss the HALT-IT Trial and its implications for clinical practice.
You can get CME credit for this episode here!Click here for CME Account Creation Instructions
As we gain more experience managing critically ill patients with COVID-19 infection there has been a shift away from immediate intubation and towards more...
Approximately 350,000 adults in the US experience an out-of-hospital cardiac arrest (OHCA). Despite numerous potential improvements in treatments, survival from OHCA remains essentially unchanged...
With increasing water temperatures, there is a rise in the incidence of V.vulnificus infections in non-endemic regions. Patients with V.vulnificus infection are often critically...
